大肠癌患者可溶性肿瘤坏死因子受体Ⅰ的检测  

Soluble tumor necresis factor (sTNF) recepter Ⅰ in patients with colorectal eancer

作　　者：白岚[1] 赖卓胜[1] 周殿元[1] 张兰兰[1] 牛杰志[1] 

机构地区：[1]第一军医大学南方医院消化疾病研究所

出　　处：《癌症》1998年第2期93-95,共3页Chinese Journal of Cancer

基　　金：广东省自然科学基金

摘　　要：目的：进一步了解大肠癌患者的异常免疫状态，探讨ｓＴＮＦＲⅠ检测的临床意义。方法：用双单抗夹心酶联免疫吸附法检测ｓＴＮＦＲⅠ含量。结果：大肠癌Ｃ期、Ｄ期病人的血ｓＴＮＦＲⅠ浓度显著高于正常对照，为１３０１９０±１３７９２０ｕ／Ｌ、２０７４００±１３７３９０ｕ／Ｌ比５１６４０±２６６７０ｕ／Ｌ。ｓＴＮＦＲⅠ升高程度及异常发生率与肿瘤分期、血ＣＥＡ的异常率有关，而与肿瘤的分化程度无关。结论：ｓＴＮＦＲⅠ的检测对协助大肠癌的早期诊断、病人复发随访及预后判断具有实用价值。Purpose: To further understand the abnormal immune status of patients with colorectal cancer and to investigate the clinical significance of detection for sTNFRⅠ concentration. Method: Two monoclonal antibodies sandwich enzyme-linked immunosorbent assay was used for determining sTNFRⅠ contents. Results: The results showed that the mean±SD concentration of sTNFRⅠ was significantly higher in the cancer patients at stage C and stage D than in the healthy controls: 130190±137920 U/L and 207400±137390 U/L versus 51640±26670 U/L. The incidence and the extent of the increase of sTNFRⅠ correlated with the staging of disease and the incidence of elevated serum CEA, not with the differentiation of tumor. Conclusions: The determination of serum levels of sTNFRⅠ may serve as a diagnostic aid in the early detection, follow-up and prognosis of colorectal cancer.

关 键 词：大肠肿瘤 STNFR-I ELISA 

分 类 号：R735.340.4[医药卫生—肿瘤] R730.43[医药卫生—临床医学]